Emmertsen K, Bjerregaard P, Andreasen F
Acta Med Scand. 1987;221(5):435-9. doi: 10.1111/j.0954-6820.1987.tb01277.x.
Amiodarone was administered to 53 patients with otherwise drug-refractory supraventricular tachycardias. Therapy was effective in 35 patients and partially effective in nine patients for a median duration of 35 months. The median maintenance dose was 200 mg/day in both groups, whereas the median serum amiodarone concentrations were 1.1 mg/l and 0.7 mg/l, respectively. Amiodarone was ineffective in nine patients despite higher dosage (median 400 mg/day) and insignificantly higher serum concentrations (median 2.0 mg/l). Neither the age of the patients, the duration or type of arrhythmia, the cardio-thoracic index, nor the type of underlying heart disease were predictive of the efficacy of amiodarone. Side-effects occurred in 28 patients, leading to withdrawal of therapy in 12 patients. Side-effects were not associated with higher serum amiodarone concentrations. Despite its efficacy, amiodarone should be reserved for otherwise drug-resistant supraventricular tachyarrhythmias.
对53例其他药物治疗无效的室上性心动过速患者给予胺碘酮治疗。35例患者治疗有效，9例患者部分有效，中位持续时间为35个月。两组的中位维持剂量均为200mg/天，而胺碘酮的中位血清浓度分别为1.1mg/L和0.7mg/L。尽管剂量较高（中位剂量为400mg/天）且血清浓度略高（中位浓度为2.0mg/L），但9例患者使用胺碘酮无效。患者的年龄、心律失常的持续时间或类型、心胸指数以及潜在心脏病的类型均不能预测胺碘酮的疗效。28例患者出现副作用，12例患者因此停药。副作用与较高的胺碘酮血清浓度无关。尽管胺碘酮有效，但应仅用于其他药物治疗无效的室上性快速性心律失常。
